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LE RS TO E EDH 
I read with interest the study of Sclfers et al. (I) on the in vitro and 
in viva inotropic effects of the beta,-agonist terbutaline. After the 
definition by our group of the role of beta,-adrenoceptw stimulation in 
the activation of adenylate cycla% and production of positive inOtrOpiC 
etfcas in vitro, we, too, have u.sed synthetic beta,-agonists, in our WC 
MlhutamoI, to explore the in vivo cffccts of beta?-adrenweptor 
stimulation (2.3). In keeping with our earlier sunlies (4). Sclfers et al 
found that b&+-agonists product? positive inotropic &feSts it1 Vitro. 
Tkcy &o ww ;~hlr: to d~~~(~~str~~t~ for the lirst time in humans a 
pushive inotropic elfcct in viva. 
of perhaps more interest is the sensitization of cardiac beta:* 
adrentxeptors induced hy b4%ii,-ill~t~lgO99iSt IICi~ttWflt~ fibt &tCCtCd in 
vitro itnd subsequently dcmonstruted in vivo (45). This linding of a 
,~~~tornll~~ et al. (0) and shown to occur despite no alteration in beta,- 
adrenoc~ptor density. In their discussio,l, Schtifers et al. compare their 
current study showing ne alteration of responsiveness to terhutaline 
.tfter 3 weeks of beta,-adrcnergic blocking agent treatment with our 
study showing increased responsiveness to intracoronary salhutamol in 
patients previously treated with beta,-blockers (L5). They speculate on 
F&Ac rea.sons why they failed to detect beta?-adrcnoceptor sensiti- 
zation during 3 weeks of treatment with hisoprolul. Some of ths 
questions raised c;ln be answered hy refcrcncc to our published study 
of the responses of normal volunteers to intravenous salbutamol after 
hisoprolol treatment (7). We fuund that in normal volunteers !. wcclks 
of treatment with hisoprolol increased cardiac responsiveness to 
bet~+tdrcnoceptur stimulation. Conscqusntly, the failure of Schiifers 
ct al, to detect beta,-adrenoccptur sensitization in viva cannot IX 
altribulcd to the use of inrravcnous infusions rather than intracoronrry 
injections nor to the use of normal volunteers rather than patients. We 
studied the responsrs to sulbutamol4ll h after withdrawal of laisoprolol 
rather than during continuing treiatmcnt be~ut.se this allowed us to 
simult~neou~~ assess ~tn,*~d~no~pto~-medinted effects. Howevur. 
continainep bisuprolol treatment (as used by Schifers et al.) should not 
have si@i~antly reducsd the responses to tcrbutalinc bccausc calcu- 
lated beta2-adrenoceptor occupnucy should be 6% (8). 
The diEerenee between the two studies is of therapeutic impor- 
tam: ki!W.usC, in S&fers et al. Spc~datc, beta,qgmists CiW be used 
in patients with heart failure to provide inotropic support. Our in vitro 
aM1 in viw findings would sugest that hisoprolol treatment will 
actually lead to enhanced beta,-adrenoceptor-mediated cardiiic re- 
SpORWS. Consequently, it is possible that an enhanced positive ino- 
tropir‘ cAk3 of the endogenous ratecholamines adrenaline and nora- 
drmline. acting through beta+rdrenoceptors, accounts for the 
bnehehl clinical effects of long-term beta,-blocker therapy seeu in 
patients with heart failure (9). Further studies are needed to examine 
this hypothesis. 
&?pg 
WC very much ~l~pre~~~~l~ the inreres1 of all in our rcccnt study on the 
in vitro md is vivo effects of t~rb~~talin~ in the human Ivan ( I ). An 
lrrescnt we do no1 know why we did not find any beta,-adrenergic 
receptor seositizrtion in the h&thy volunteers afIcr the ~-WC& 
trCiitIjIont with the het;r,-adrenergic receptor-selective antagonist 
bisoprolol (IO mg). whereas Hall et al. (2,3) did tind such sensitization 
in pikItS with coronary artery discasc ilftCr long-term treatment with 
the beta,-adrent@ rcccptor-sclectivvs antagonist iitenolol(2) and in 
healthy volunteers uftcr long-term treatment with the beta,-adrenergic 
receptor-selective antagonist bis~lpr~~!ol (3). In our study (I) WC 
speculated that the dilferencc ~wuld be due to the injection of 
salbutamnl in tbc right coronary artery of patients in the Hall et al. (2) 
study. whsrens terh~talin~ was infused intravenously in volunteers in 
our study, hut this does nut !tppear to he the reason bccausc Hall et al. 
also infused intravenous salbutamol in healthy volunteers and obtained 
an increased heart rate response to salbutamol after bisoprolol treat- 
ment (3). Thus, the main difference between the two studies in 
volunteers (1.3) is &at we examined the effects of terhutaline during 
continuous bisoprolol treatment, whereas Hall et al. examined the 
effects of salbutamol48 h after withdrawal of bisoprolol. However, the 
sensitizing effect of bisoprolol on salbutamol infusion-induced tachy- 
cardia in the volunteers was much weaker than on intracoronary 
salbutamol-induced tachgcardia in the patients with coronary artery 
disease. In the volunteers the dose at which salbutamol increased heart 
rate by 40 beats/mitt was 2.9 rcgkg before and I.9 pg./kg after 
hisoprolol treatment (rntio 1.5). and dilferences were obvious only at 
the hvo highest doses of salbutamol (3), whereas after intracoronary 
injections in the patients. the dose at which salbutamol increased heart 
rate by 30 beatslmin was 8.91 pg before and 2.29 erg after atenolol 
(ratic 3.9), and at each dose salb~tamol was more elfective in the 
atenolol-treated patients than in the nontreated patients (2). We 
believe that this is at least partly in line with our view that the major 
difference between our data and those of Hall et al. is the comparison 
of volunteers with patients and intravenous infusion with intracoronary 
